Clinical Study

n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich Lipoprotein Kinetics in Men with Type 2 Diabetes

Table 1

Characteristics and fasting lipid/lipoprotein profile of the evaluated patients with type 2 diabetes.

Placebo ()n-3 PUFA ()%

Body weight, kg106.1 ± 19.5105.8 ± 21.0−0.30.7
Body mass index, kg/m234.1 ± 5.534.1 ± 6.10.7
Serum
 Cholesterol, mmol/L4.68 ± 0.804.96 ± 0.58+6.00.05
 Triglycerides, mmol/L2.58 ± 1.122.33 ± 0.94−9.70.05
 LDL-cholesterol, mmol/L2.55 ± 0.722.86 ± 0.47+12.20.04
 HDL-cholesterol, mmol/L0.95 ± 0.171.03 ± 0.20+8.40.007
 Apolipoprotein B, g/L1.00 ± 0.191.03 ± 0.11+3.00.4
 Apolipoprotein AI, g/L1.12 ± 0.181.15 ± 0.14+2.60.4
Glucose homeostasis
 Glucose, mmol/L7.3 ± 1.68.1 ± 2.2+11.00.3
 Insulin, mol/L147 ± 86164 ± 109+11.90.6
 HbA1c0.070 ± 0.0100.072 ± 0.011+2.90.1

PUFA: polyunsaturated fatty acid.
Mean ± SD; % represents the percentage of difference between the two intervention phases.